Contemporary Management of HIV: Modifying ART in Virologically Suppressed Patients

Download this expert-authored slideset to review guidelines and key data on assessing virologic failure, current management options for patients with multiclass drug resistance experiencing treatment failure, and considerations for switching ART in patients with underlying resistance.
Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Paul E. Sax, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 629 KB
Released: March 2, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
ViiV Healthcare

Related Content

CCO commentary by Professor Don Smith on CROI 2021 data on ARV-associated weight gain and long-acting injectable ART

person default Don Smith, MD Released: April 20, 2021

Drs Monica Gandhi and Joseph Eron discuss next-line ART options for a heavily treatment-experienced patient with multiclass resistance .

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 19, 2021 Expired: April 18, 2022

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Released: April 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue